Monopar Therapeutics Inc. (MNPR) Financial Statements (2024 and earlier)

Company Profile

Business Address 1000 SKOKIE BLVD SUITE 350
WILMETTE, IL 60091
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:7,26612,18220,30416,73713,2146,893
Cash and cash equivalents7,2668,18620,30416,73713,2146,893
Other undisclosed cash, cash equivalents, and short-term investments  3,996    
Deferred costs     10 
Other current assets664621863  
Other undisclosed current assets 937  5425
Total current assets:7,33313,16620,52216,80013,2307,318
Noncurrent Assets
Operating lease, right-of-use asset 1361   
Other noncurrent assets    69122 
Total noncurrent assets: 1361 69122 
TOTAL ASSETS:7,34513,22720,52216,86913,3527,318
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,7573,1291,5811,177724400
Other undisclosed accounts payable and accrued liabilities1,7573,1291,5811,177724400
Total current liabilities:1,7573,1291,5811,177724400
Noncurrent Liabilities
Liabilities, other than long-term debt  8    
Operating lease, liability  8   
Total noncurrent liabilities:  8    
Total liabilities:1,7573,1371,5811,177724400
Equity
Equity, attributable to parent5,58810,09018,94115,69212,6286,918
Common stock15131311119
Additional paid in capital65,79361,87260,22047,87438,50928,567
Accumulated other comprehensive income (loss)(14)9(3)(8)(11)(2)
Accumulated deficit(60,206)(51,804)(41,288)(32,185)(25,881)(21,656)
Total equity:5,58810,09018,94115,69212,6286,918
TOTAL LIABILITIES AND EQUITY:7,34513,22720,52216,86913,3527,318

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues
(Other Income)
    122  
Cost of revenue
(Cost of Goods and Services Sold)
  (83)    
Gross profit:  (83) 122  
Operating expenses(8,831)(10,537)(9,127)(6,509)(4,324)(3,403)
Other undisclosed operating income (loss)  83 (122)  
Operating loss:(8,831)(10,537)(9,127)(6,509)(4,324)(3,403)
Loss from continuing operations before equity method investments, income taxes:(8,831)(10,537)(9,127)(6,509)(4,324)(3,403)
Other undisclosed income from continuing operations before income taxes      103
Loss from continuing operations:(8,831)(10,537)(9,127)(6,509)(4,324)(3,300)
Loss before gain (loss) on sale of properties:(9,127)(6,509)(4,324)(3,300)
Other undisclosed net income  21    
Net loss:(8,831)(10,516)(9,127)(6,509)(4,324)(3,300)
Other undisclosed net income attributable to parent429 242049972
Net loss available to common stockholders, diluted:(8,402)(10,516)(9,103)(6,305)(4,225)(3,228)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(8,831)(10,516)(9,127)(6,509)(4,324)(3,300)
Other comprehensive income (loss)  1253(9)(2)
Comprehensive loss:(8,831)(10,504)(9,123)(6,506)(4,332)(3,302)
Other undisclosed comprehensive income, net of tax, attributable to parent406 242049972
Comprehensive loss, net of tax, attributable to parent:(8,425)(10,504)(9,099)(6,301)(4,233)(3,230)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: